Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
MIF is a proinflammatory cytokine and is implicated in cancer. A higher MIF level is found in many human cancer and cancer‐prone inflammatory diseases, including chronic pancreatitis and pancreatic cancer. We tested the hypothesis that MIF contributes to pancreatic cancer aggressiveness and predicts disease outcome in resected cases. Consistent with our hypothesis we found that an elevated MIF mRNA expression in tumors was significantly associated with poor outcome in resected cases. Multivariate Cox‐regression analysis further showed that MIF is independently associated with patients' survival (HR = 2.26, 95% CI = 1.17–4.37, p = 0.015). Mechanistic analyses revealed that MIF overexpression decreased E‐cadherin and increased vimentin mRNA and protein levels in pancreatic cancer cell lines, consistent with the features of epithelial‐to‐mesenchymal transition (EMT). Furthermore, MIF‐overexpression significantly increased ZEB1/2 and decreased miR‐200b expression, while shRNA‐mediated inhibition of MIF increased E‐cadherin and miR‐200b expression, and reduced the expression of ZEB1/2 in Panc1 cells. Re‐expression of miR‐200b in MIF overexpressing cells restored the epithelial characteristics, as indicated by an increase in E‐cadherin and decrease in ZEB1/2 and vimentin expression. A reduced sensitivity to the chemotherapeutic drug, gemcitabine, occurred in MIF‐overexpressing cells. Indicative of an increased malignant potential, MIF over‐expressing cells showed significant increase in their invasion ability in vitro, and tumor growth and metastasis in an orthotopic xenograft mouse model. These results support a role of MIF in disease aggressiveness, indicating its potential usefulness as a candidate target for designing improved treatment in pancreatic cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Hidalgo, M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0901557 · Cited by 2,570
EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer
Singh, A., & Settleman, J. (2010) · Oncogene · doi:10.1038/onc.2010.215 · Cited by 2,545
EMT and Dissemination Precede Pancreatic Tumor Formation
Rhim, A. D., Mirek, E. T., Aiello, N. M., Maitra, A., Bailey, J. M., McAllister, F., Reichert, M., Beatty, G. L., Rustgi, A. K., Vonderheide, R. H., et al. (2012) · Cell · doi:10.1016/j.cell.2011.11.025 · Cited by 2,136 · cited 2×
“Interestingly, pancreatic cancer cells attain invasive properties at an earlier stage of tumor development, which is aided by EMT in an inflammatory microenvironment.(10) These observations underscore the contribution of EMT in pancreatic tumor progression and suggest that inflammation may contribute to the induction…”
BackgroundSelf-citationHussain, S. P., Hofseth, L. J., & Harris, C. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1046 · Cited by 1,690 · cited 1×
“Increase in the level of cytokines, generation of reactive oxygen and nitrogen species, alteration in miRNA expressions, and induction of NF-kB are some of the major inflammation-mediated events that may contribute to the development and progression of cancer.(8,9) Inflammation enhances tumor progression and cancer ce…”
BackgroundSelf-citationA Proinflammatory Cytokine Inhibits P53 Tumor Suppressor Activity
Hudson, J. D., Shoaibi, M. A., Maestro, R., Carnero, A., Hannon, G. J., & Beach, D. H. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.10.1375 · Cited by 649 · cited 1×
“Many functions of MIF support its potential involvement in tumorigenesis, for example, MIF functions as a negative regulator of p53 and antagonizes p53-mediated growth arrest and apoptosis.(18) It initiates a cascade of events leading to the phosphorylation of ERK1/ERK2, induction of cytoplasmic phospholipase A2, COX2…”
BackgroundIncreased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients
Glynn, S. A., Boersma, B. J., Dorsey, T. H., Yi, M., Yfantis, H. G., Ridnour, L. A., Martin, D. N., Switzer, C. H., Hudson, R. S., Wink, D. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci42059 · Cited by 254 · cited 1×
“Immunostaining was evaluated blindly by a board-certified pathologist assigning the intensity and prevalence score as described elsewhere.(19) Briefly, the intensity was assigned a score of 0-3, representing negative, weak, moderate or strong expression, whereas, prevalence was assigned a score of 0-4 representing <10…”
MethodSelf-citation
Cited by
Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver
Costa-Silva, B., Aiello, N. M., Ocean, A. J., Singh, S., Zhang, H., Thakur, B. K., Becker, A., Hoshino, A., Mark, M. T., Molina, H., et al. (2015) · Nature Cell Biology · doi:10.1038/ncb3169 · Cited by 2,692
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527
Salcher, S., Sturm, G., Horvath, L., Untergasser, G., Kuempers, C., Fotakis, G., Panizzolo, E., Martowicz, A., Trebo, M., Pall, G., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.10.008 · Cited by 477
A Novel MIF Signaling Pathway Drives the Malignant Character of Pancreatic Cancer by Targeting NR3C2
Yang, S., He, P., Wang, J., Schetter, A., Tang, W., Funamizu, N., Yanaga, K., Uwagawa, T., Satoskar, A. R., Gaedcke, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2841 · Cited by 393
Self-citationLee, J. J., Bernard, V., Semaan, A., Monberg, M. E., Huang, J., Stephens, B. M., Lin, D., Rajapakshe, K. I., Weston, B. R., Bhutani, M. S., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3925 · Cited by 128
“This interaction has been implicated in promoting myeloid-derived suppressor cell–mediated immunosuppression in melanoma and breast cancer (34, 35), while tumor-cell MIF expression has been linked to a more aggressive phenotype in PDAC (36).”
BackgroundSelf-citation
Metadata
- Authors
- Funamizu, N., Hu, C., Lacy, C., Schetter, A., Zhang, G., He, P., Gaedcke, J., Ghadimi, M. B., Ried, T., Yfantis, H. G., Lee, D. H., Subleski, J., Chan, T., Weiss, J. M., Back, T. C., Yanaga, K., Hanna, N., Alexander, H. R., Maitra, A., & Hussain, S. P.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2012-09-14
- Volume
- 132
- Issue
- 4
- Pages
- 785-794
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2029665800
- Cited by
- 133
- References
- 8
- FWCI
- 2.10
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. https://app.cochat.ai/papers/10.1002/ijc.27736
- The paper
- Funamizu, N., Hu, C., Lacy, C., Schetter, A., Zhang, G., He, P., Gaedcke, J., Ghadimi, M. B., Ried, T., Yfantis, H. G., Lee, D. H., Subleski, J., Chan, T., Weiss, J. M., Back, T. C., Yanaga, K., Hanna, N., Alexander, H. R., Maitra, A., & Hussain, S. P. (2013). Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. International Journal of Cancer. https://doi.org/10.1002/ijc.27736
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.